A study finds that removing accumulated circular RNA slows aging and extends lifespan, with an enzyme preventing toxic RNA buildup, and supporting healthy cellular function across organisms.
In drug discovery, very little of what’s learned from one project can typically be carried over to the next. “For every new target you go after with a small molecule, you basically start from scratch, ...
Nutcracker Therapeutics is driving down costs, accelerating speed of processing and improving scalability with an end-to-end, GMP-grade production process. Healthcare is on the cusp of a ...
The recognition of mRNA molecules as a transformative class of therapeutic drugs has soared, particularly with the development of COVID 19 mRNA vaccines. The cancer treatment landscape is similarly ...
Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...
The Carnegie Institution for Science and the University of Massachusetts Medical School (UMMS) have been granted United States Patent 8,283,329, entitled, "Genetic inhibition of double-stranded RNA." ...
Hosted on MSN
UNC advances RNAi potency platform
Researchers at the University of North Carolina at Chapel Hill have unveiled a platform technology designed to strengthen the potency of RNA interference therapies, a field that has promised targeted ...
Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results